Type 1 diabetics, armed with glucose meters and insulin pens, are caught in a delicate high-wire act. Too much glucose wreaks havoc on nerves and blood vessels, while too little causes dizziness and nausea. A Cleveland biotech company is trying to change that by delivering insulin to the liver, where it naturally goes.

Diasome has three phase 2 clinical trials in progress testing nanoparticles known as hepatocyte-directed vesicles. These particles, smaller than the period at the end of this sentence, stick to insulin like Velcro and bring it to the liver. Diasome believes its approach will better manage patients’ blood sugar than administering insulin alone.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

    • Diane, I am a Type 2 Diabetic and are all for promising new therapies. However, I’m also a biochemist and have concerns about targeting the liver directly with insulin. While it is true that insulin delivered to the liver suppresses glucose production, thereby lowering blood glucose levels, that same insulin stimulates the liver to increase triglyceride (fat) production, release these fatty substances into the blood and if present in sufficient quantities these elevated triglyceride levels in the blood can CAUSE insulin resistance, which seems to be somewhat self defeating. This compound needs to get a hard long look from a metabolic basis as it proceeds through clinical trials.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy